Italia markets closed

RANI Jun 2024 7.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,10000,0000 (0,00%)
Alla chiusura: 03:34PM EDT
Schermo intero
Chiusura precedente0,1000
Aperto0,1500
Denaro0,0000
Domanda0,7500
Prezzo d'esercizio7,50
Scadenza2024-06-21
Min-Max giorno0,1000 - 0,1500
Contratto - Min-MaxN/D
Volume165
Open Interest262
  • GlobeNewswire

    Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

    SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada. The details of the presentation are as follows: A

  • GlobeNewswire

    Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

    - Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an oral

  • GlobeNewswire

    Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

    - Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance - Increased payload of up to 20mg enables potential delivery of 90+ additional drug candidates - SAN JOSE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA